The added value of type I interferons to cytotoxic treatments of cancer
- 1 August 2017
- journal article
- review article
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 36, 89-97
Abstract
No abstract availableKeywords
This publication has 96 references indexed in Scilit:
- Type I interferons in anticancer immunityNature Reviews Immunology, 2015
- Twenty-five years of type I interferon-based treatment: A critical analysis of its therapeutic useCytokine & Growth Factor Reviews, 2015
- NK cells and interferonsCytokine & Growth Factor Reviews, 2015
- Role of type I interferon in inducing a protective immune response: Perspectives for clinical applicationsCytokine & Growth Factor Reviews, 2015
- Interferon-α as Antiviral and Antitumor Vaccine Adjuvants: Mechanisms of Action and Response SignatureJournal of Interferon & Cytokine Research, 2012
- Regulation of effector and memory T-cell functions by type I interferonImmunology, 2011
- Type I interferon: friend or foe?Journal of Experimental Medicine, 2010
- Mechanisms of type-I- and type-II-interferon-mediated signallingNature Reviews Immunology, 2005
- Type I Interferon as a Powerful Adjuvant for Monocyte-Derived Dendritic Cell Development and Activity in Vitro and in Hu-Pbl-Scid MiceJournal of Experimental Medicine, 2000
- Antitumor effects of interferon in mice injected with interferon‐sensitive and interferon‐resistant friend leukemia cells. I.International Journal of Cancer, 1982